Keyword Analysis & Research: pfizer biontech
Keyword Research: People who searched pfizer biontech also searched
Search Results related to pfizer biontech on Search Engine
-
Pfizer–BioNTech COVID-19 vaccine - Wikipedia
https://en.wikipedia.org/wiki/Pfizer%E2%80%93BioNTech_COVID-19_vaccine
Web ResultThe Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials , logistics, and manufacturing.
DA: 53 PA: 83 MOZ Rank: 75
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full
Web ResultDec 11, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY ® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in …
DA: 84 PA: 23 MOZ Rank: 78
-
Pfizer-BioNTech COVID-19 Vaccine | Pfizer
https://www.pfizer.com/products/product-detail/pfizer-biontech-covid-19-vaccine
Web ResultPfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 6 months through 11 years of age.
DA: 55 PA: 4 MOZ Rank: 33
-
Pfizer and BioNTech Announce Further Details on Collaboration …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-further-details-collaboration
Web ResultApr 9, 2020 · MAINZ, Germany & NEW YORK--(BUSINESS WIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.
DA: 46 PA: 64 MOZ Rank: 43
-
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing
Web ResultOct 21, 2021 · Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine. Thursday, October 21, 2021 - 06:45am. View pdf copy Copy to clipboard Open in tab.
DA: 99 PA: 16 MOZ Rank: 85
-
FDA Approves First COVID-19 Vaccine | FDA
https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
Web ResultAug 23, 2021 · For Immediate Release: August 23, 2021. Español. Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19...
DA: 71 PA: 96 MOZ Rank: 59
-
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-covid-19-vaccine-data
Web ResultAug 23, 2022 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, …
DA: 87 PA: 28 MOZ Rank: 48
-
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
Web ResultNov 18, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary …
DA: 4 PA: 74 MOZ Rank: 28
-
Pfizer and BioNTech Share Positive Early Data on Lead mRNA …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-share-positive-early-data-lead-mrna
Web ResultAug 20, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase …
DA: 49 PA: 22 MOZ Rank: 83
-
The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you …
https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine-what-you-need-to-know
Web ResultAug 18, 2022 · The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19. This article provides a summary of those interim recommendations; you may access the full guidance document here .
DA: 62 PA: 19 MOZ Rank: 69